tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Cognition Therapeutics announces Phase 2 ‘START’ study surpassed 50% enrollment
PremiumThe FlyCognition Therapeutics announces Phase 2 ‘START’ study surpassed 50% enrollment
22d ago
Cognition Therapeutics Advances with CT1812 in Dementia Study
Premium
Company Announcements
Cognition Therapeutics Advances with CT1812 in Dementia Study
23d ago
Cognition to conduct end-of-Phase 2 meeting with FDA on zervimesine
Premium
The Fly
Cognition to conduct end-of-Phase 2 meeting with FDA on zervimesine
28d ago
Cognition Therapeutics Advances to Phase 3 Trials
PremiumCompany AnnouncementsCognition Therapeutics Advances to Phase 3 Trials
2M ago
Cognition Therapeutics price target lowered to $3 from $5 at H.C. Wainwright
Premium
The Fly
Cognition Therapeutics price target lowered to $3 from $5 at H.C. Wainwright
2M ago
Cognition Therapeutics presents preclinical data on zervimesine at ARVO
Premium
The Fly
Cognition Therapeutics presents preclinical data on zervimesine at ARVO
3M ago
Cognition Therapeutics sees cash runway into 4Q25
PremiumThe FlyCognition Therapeutics sees cash runway into 4Q25
3M ago
Cognition Therapeutics presents results at AD/PD 2025 on CT1812
Premium
The Fly
Cognition Therapeutics presents results at AD/PD 2025 on CT1812
4M ago
Buy Recommendation for Cognition Therapeutics: Promising Phase 2 Results and Strategic Focus on Alzheimer’s and Dementia Indications
Premium
Ratings
Buy Recommendation for Cognition Therapeutics: Promising Phase 2 Results and Strategic Focus on Alzheimer’s and Dementia Indications
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100